Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience

BACKGROUND: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. We recently published the first data on the use of iv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimini, Margherita, Burgio, Valentina, Antonuzzo, Lorenzo, Rimassa, Lorenza, Oneda, Ester, Soldà, Caterina, Cito, Pasqua, Nasti, Guglielmo, Lavacchi, Daniele, Zanuso, Valentina, Rizzato, Mario Domenico, Zaniboni, Alberto, Ottaiano, Alessandro, Persano, Mara, Cornara, Noemi, Scartozzi, Mario, Cascinu, Stefano, Casadei-Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345913/
https://www.ncbi.nlm.nih.gov/pubmed/37457302
http://dx.doi.org/10.1177/17588359231171574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345913/
https://www.ncbi.nlm.nih.gov/pubmed/37457302
http://dx.doi.org/10.1177/17588359231171574

Ejemplares similares